Compounds and compositions as protein kinase inhibitors

Abstract

The invention relates to compounds of formula (I) wherein the substituents X 1 , R 1 , R 2 , R 3 and R 4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

1 . A method for the treatment of cancer comprising administering an effective amount of a compound of Formula (I) to an animal in need of treatment thereof: 
       
         
           
           
               
               
           
         
       
       where
 the following fragments referred to hereinafter as the “left hand ring” and the “right hand ring”, respectively: 
 
       
         
           
           
               
               
           
         
         wherein X is C—R 5 , and Y and Z are both N, whereby the left hand ring has the structure of Fragment (A): 
       
       
         
           
           
               
               
           
         
         n is 0, 1, 2, 3, 4 or 5; 
         X 1  is oxygen, 
         R 1  is of the formula R z —NR a — wherein R a  is hydrogen, hydroxy, hydrocarbyloxy or hydrocarbyl, wherein hydrocarbyl has from 1 to 15 carbon atoms, is optionally interrupted by an —O— or —NH-linkage and is unsubstituted or is substituted by hydroxy, halo, amino or mono- or di-(C 1 -C 4 )alkylamino, alkanoyl having 4 in-chain atoms, trifluoromethyl, cyano, azo or nitro; and R z  is selected from: 
         (i) linear or branched alkyl having 1, 2, 3 or 4 carbon atoms, 
         (ii) linear or branched alkyl having 1, 2, 3 or 4 carbon atoms substituted by one or more halogens and/or one or two functional groups selected from hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, acyl having 1, 2, 3 or 4 carbon atoms, acyloxy having 1, 2, 3 or 4 carbon atoms, carboxy, sulfo, sulfamoyl, carbamoyl, cyano, azo, or nitro, which hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, carboxy, sulfo, sulfamoyl, carbamoyl and cyano groups are in turn optionally substituted on at least one heteroatom by one or, where possible, more linear or branched alkyl groups having 1, 2, 3 or 4 carbon atoms, and 
         (iii) a group of the formula 
       
       
         
           
           
               
               
           
         
       
       where:
 ring A represents a 6-membered carbocyclic or heterocyclic ring; 
 m is 0, 1 or 2; 
 each R b  is independently selected from -L 2 -NR c R d ; -L 2 -RING where RING is a mono- or bi-cyclic ring optionally substituted as defined below; halogen; hydroxy; protected hydroxyl; amino; amidino; guanidino; hydroxyguanidino; formamidino; isothioureido; ureido; mercapto; acyl having 4 in-chain atoms; acyloxy having 4 in-chain atoms; carboxy; sulfo; sulfamoyl; carbamoyl; cyano; azo; or nitro; and linear or branched alkyl having 1, 2, 3 or 4 carbon atoms optionally substituted by one or more halogens and/or one or two functional groups selected from hydroxy, protected hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, acyl having 4 in-chain atoms, acyloxy having 4 in-chain atoms, carboxy, sulfo, sulfamoyl, carbamoyl, cyano, azo, or nitro; all of which hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, carboxy, sulfo, sulfamoyl, carbamoyl and cyano groups are in turn optionally substituted on at least one heteroatom by one or, where possible, more C 1 -C 7  aliphatic groups, 
 wherein L 2  is a direct bond; a linkage selected from —O—; —S—; —C(O)—; —OC(O)—; —NR a C(O)—; —C(O)—NR a —; —OC(O)—NR a —; cyclopropyl and —NR a —; or is a linear or branched alkyl group having 1, 2, 3 or 4 carbon atoms optionally interrupted and/or terminated at a single end or at both ends by a said linkage; 
 and wherein R c  and R d  are each independently selected from hydrogen, and linear or branched alkyl having 1, 2, 3 or 4 carbon atoms optionally substituted by one or more halogens, by an optionally substituted 5- or 6-membered heterocyclic or carbocyclic ring, and/or one or two functional groups selected from hydroxy, protected hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, acyl having 4 in-chain atoms, acyloxy having 4 in-chain atoms, carboxy, sulfo, sulfamoyl, carbamoyl, cyano, azo, or nitro, which hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, carboxy, sulfo, sulfamoyl, carbamoyl and cyano groups are in turn optionally substituted on at least one heteroatom by one or more C 1 -C 7  aliphatic groups, 
 or R c  and R d  together with their adjoining nitrogen form a 5- or 6-membered ring optionally substituted as described below, 
 said optionally substituted rings independently of each other being substituted by 0, 1, 2, 3, 4 or 5 substituents selected from halogen; hydroxy; protected hydroxy; amino; amidino; guanidino; hydroxyguanidino; formamidino; isothioureido; ureido; mercapto; acyl having 4 in-chain atoms; acyloxy having 4 in-chain atoms; carboxy; sulfo; sulfamoyl; carbamoyl; cyano; azo; nitro; C 1 -C 7  aliphatic optionally substituted by one or more halogens and/or one or two functional groups selected from hydroxy, protected hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, acyl having 4 in-chain atoms, acyloxy having 4 in-chain atoms, carboxy, sulfo, sulfamoyl, carbamoyl, cyano, azo, or nitro; all of the aforesaid hydroxy, amino, amidino, guanidino, hydroxyguanidino, formamidino, isothioureido, ureido, mercapto, carboxy, sulfo, sulfamoyl and carbamoyl groups in turn optionally being substituted on at least one heteroatom by one or, where possible, more C 1 -C 7  aliphatic groups; 
 R 2  is H, halo, alkyl, alkyl interrupted by an —O— or —NH— linkage and/or linked to the left hand ring by a said linkage, trifluoromethyl, hydroxy, amino, mono- or dialkylamino; any alkyl moiety (interrupted or not) having 1, 2, 3 or 4 carbon atoms; 
 R 3  is H, a straight chain or branched C 1 -C 4  alkyl or a straight chain or branched C 1 -C 4  alkyl substituted by a 5- or 6-membered saturated or unsaturated carbocyclic or heterocyclic ring; 
 R 4  is selected from hydroxy, protected hydroxy, alkoxy, alkyl, trifluoromethyl and halo, wherein alkyl and the alkyl part of alkoxy are branched or straight chain and have 1, 2, 3, or 4 carbon atoms, or; 
 R 5  is H, halo, alkyl, alkyl interrupted by an —O— or —NH— linkage and/or linked to the left hand ring by a said linkage, trifluoromethyl, hydroxy, amino, mono- or dialkylamino; any alkyl moiety (interrupted or not) having 1, 2, 3 or 4 carbon atoms,
 or pharmaceutically acceptable salts, esters, N-oxides, protected derivatives, individual isomers and mixture of isomers thereof. 
 
 
     
     
         2 . The method of  claim 1  wherein R 5  is H or halo. 
     
     
         3 . The method of  claim 1  wherein R 5  is H. 
     
     
         4 . The method of  claim 1  wherein, R 2  is H. 
     
     
         5 . The method of  claim 1  wherein the left hand ring has the structure of Fragment (B): 
       
         
           
           
               
               
           
         
       
     
     
         6 . The method of  claim 1  wherein R z  is of the formula 
       
         
           
           
               
               
           
         
       
     
     
         7 . The method of  claim 6  which wherein the compound of Formula (I) comprises at least one R b  which is -L 2 -NR c R d  or -L 2 -RING, wherein L 2  is a direct bond, linear alkyl, linear alkyl terminated adjacent ring A by a linkage selected from —O—; —S—; —C(O)—; —OC(O)—; —NR a C(O)—; —C(O)—NR a —; —OC(O)—NR a —; cyclopropyl and —NR a —; or is a linkage selected from —O—; —S—; —C(O)—; —OC(O)—; —NR a C(O)—; —C(O)—NR a —; —OC(O)—NR a —; cyclopropyl and —NR a —. 
     
     
         8 . The method of  claim 7  wherein said linkage is —O—. 
     
     
         9 . The method of  claim 6  wherein ring A is phenyl, cyclohexenyl or cyclohexyl. 
     
     
         10 . The method of  claim 6  wherein there is a single R b  group which is selected from -L 2 -NR c R d  and -L 2 -RING and there are 0, 1 or 2 additional substituents which are selected from halogen, alkyl, alkoxy, hydroxy, amino and trifluoromethyl, wherein alkyl and the alkyl part of alkoxy have 1, 2, 3 or 4 carbon atoms. 
     
     
         11 . The method of  claim 1  wherein m is 1. 
     
     
         12 . The method of  claim 11  wherein ring A is phenyl or cyclohexyl and R b  is selected from -L 2 -NR c R d  and -L 2 -RING. 
     
     
         13 . The method of  claim 12  wherein the substituent is at the 3-position or 4-position of ring A. 
     
     
         14 . The method of  claim 1  wherein the left hand ring has a structure corresponding to Fragment (D1), (D2), (E1) or (E2): 
       
         
           
           
               
               
           
         
       
     
     
         15 . The method of  claim 14  wherein R a  is H. 
     
     
         16 . The method of  claim 14  wherein the phenyl ring of said Fragments has 1, 2, 3 or 4 further substituents, selected from halogen, methyl, methoxy and trifluoromethyl. 
     
     
         17 . The method of  claim 14  wherein RING is a saturated heterocycle which contains an in-ring nitrogen. 
     
     
         18 . The method of  claim 14  which contains a moiety NR c R d  and wherein R c  and R d  are the same or different and selected from straight chain or branched alkyl having 1, 2, 3 or 4 carbon atoms. 
     
     
         19 . The method of  claim 14  which contains a moiety NR c R d  and wherein R c  and R d  together with the adjoining nitrogen form a 5- or 6-membered heterocyclic ring, optionally substituted as by 0, 1, 2, 3, 4 or 5 substituents selected from straight chain or branched C 1 , C 2 , C 3  or C 4  alkyl, halogen and C 1 , C 2 , C 3  or C 4  alkoxy, wherein alkyl and the alkyl part of alkoxy are unsubstituted or substituted by halogen. 
     
     
         20 . The method of  claim 19  wherein the heterocycle is saturated. 
     
     
         21 . The method of  claim 20  wherein L 2 NR c R d  is selected from the group consisting of piperazine, morpholine, —OCH 2 piperazine, —OCH 2 -morpholine, —OCH 2 CH 2 piperazine, —OCH 2 CH 2 -morpholine, —OCH 2 CH 2 CH 2 piperazine, —OCH 2 CH 2 CH 2 -morpholine, —CH 2 piperazine, —CH 2 -morpholine, —CH 2 CH 2 piperazine, —CH 2 CH 2 -morpholine, —CH 2 CH 2 CH 2 piperazine, —CH 2 CH 2 CH 2 -morpholine, —C(O)piperazine and —C(O)morpholine, piperazine optionally being N-substituted by straight chain or branched C 1 , C 2 , C 3  or C 4  alkyl. 
     
     
         22 . The method of  claim 14  wherein the left hand ring has the structure of the following Fragment (F): 
       
         
           
           
               
               
           
         
       
     
     
         23 . The method of  claim 1  wherein n is 1, 2, 3 or 4. 
     
     
         24 . The method of  claim 1  wherein R 4  is selected from hydroxy, protected hydroxy, alkoxy, alkyl, trifluoromethyl and halo, wherein alkyl and the alkyl part of alkoxy are branched or straight chain and have 1, 2, 3, or 4 carbon atoms. 
     
     
         25 . The method of  claim 24  wherein R 4  is selected from Cl, F, hydroxy, methyl, methoxy and trifluoromethyl. 
     
     
         26 . The method of  claim 1  wherein the right hand ring corresponds to Fragment (G): 
       
         
           
           
               
               
           
         
         where: 
         Q is selected from F and Cl; 
         U is selected from H, F, Cl, methyl, trifluoromethyl and methoxy; 
         T and V are the same or different and selected from H, methyl, trifluoromethyl and methoxy. 
       
     
     
         27 . The method of  claim 26  wherein the right hand ring is Fragment (H): 
       
         
           
           
               
               
           
         
       
     
     
         28 . The method of  claim 1  wherein the right hand ring corresponds to Fragment (I): 
       
         
           
           
               
               
           
         
         where: 
         Q is selected from F and Cl; 
         U a  and U b  are each independently selected from H, F, Cl, methyl, trifluoromethyl and methoxy. 
       
     
     
         29 . The method of  claim 1  wherein the compound of Formula (I) is selected from the following formulae (IV), (V), (VI) and (VII): 
       
         
           
           
               
               
           
         
       
       where
 L 2 NR c R d  is piperazine, morpholine, —OCH 2 piperazine, —OCH 2 -morpholine, —OCH 2 CH 2 piperazine, —OCH 2 CH 2 -morpholine, —OCH 2 CH 2 CH 2 piperazine, —OCH 2 CH 2 CH 2 -morpholine, —CH 2 piperazine, —CH 2 -morpholine, —CH 2 CH 2 piperazine, —CH 2 CH 2 -morpholine, —CH 2 CH 2 CH 2 piperazine, —CH 2 CH 2 CH 2 -morpholine, —C(O)piperazine or —C(O)morpholine, wherein morpholine is optionally substituted by C 1 -C 4  alkyl and piperazine is optionally substituted by C 1 -C 4  alkyl; 
 L 2 RING is -RING, —OCH 2 RING, —OCH 2 CH 2 RING, —OCH 2 CH 2 CH 2 RING, —CH 2 RING, —CH 2 CH 2 RING, —CH 2 CH 2 CH 2 RING, and, or is —C(O)RING, where RING is a heterocycle optionally substituted by C 1 -C 4  alkyl or C 1 -C 4  haloalkyl and selected from pyrrolidine, piperidine, piperazine or morpholine; 
 R 3  is H; 
 R 4  is selected from Cl, F, hydroxy, methyl, methoxy and trifluoromethyl; 
 n is 0, 1, 2, 3, 4 or 5. 
 
     
     
         30 . The method according to  claim 1  wherein a compound of Formula (I) is administered in combination with (N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine. 
     
     
         31 . The method of  claim 1  wherein the compound of Formula (I) is selected from
 3-(2,6-Dichloro-3-methoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3-Methoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-py-rimidin-4-yl}-urea; 
 1-(3-Methoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-py-rimidin-4-yl}-urea; 
 1-(3,5-Dichloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Dichloro-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,5-Dimethoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2,5-Dimethoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-{6-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-3-(3,4,5-trimethoxy-phenyl)-urea; 
 1-{6-[3-(4-Methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-3-(3,4,5-trimethoxy-phenyl)-urea; 
 1-(2,4-Dimethoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2,4-Dimethoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Dimethoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Dimethoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Bis-trifluoromethyl-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Bis-trifluoromethyl-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Dimethyl-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3,5-Dimethyl-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3-Chloro-4-methoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3-Chloro-4-methoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(5-Methoxy-2-methyl-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(5-Methoxy-2-methyl-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-5-methoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-5-methoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3,4-Dimethoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(3,4-Dimethoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(4-Fluoro-3-methoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(4-Fluoro-3-methoxy-phenyl)-3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(4,5-Dimethoxy-2-methyl-phenyl) 3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(4,5-Dimethoxy-2-methyl-phenyl) 3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-3-methoxy-phenyl) 3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-3-methoxy-phenyl)-3-{6-[3-(2-morpholin-4-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl)-3-(6-methylamino-pyrimidin-4-yl)-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl)-3-(6-phenylamino-pyrimidin-4-yl)-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl) 3-{6-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-3,5-dimethoxy-2-methyl-phenyl) 3-{6-[3-(4-methyl-piperazin-1-yl)-phenyl-amino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl)-3-{6-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl)-3-{6-[3-(2-dimethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl)-3-{6-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-3,5-dimethoxy-phenyl)-3-{6-[3-(2-morpholin-4-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,3-Dimethoxy-phenyl)-1-ethyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(3,5-Dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(3,5-Dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-methyl-1-(6-phenylamino-pyrimidin-4-yl)-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-{6-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-{6-[3-(2-dimethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-ethyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-thiophen-2-ylmethyl-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-[2-(4-methyl-piperazin-1-yl)-ethyl]-1-(6-phenylamino-pyrimidin-4-yl)-urea; 
 3-(2-Chloro-3,5-dimethoxy-phenyl)-1-(6-phenylamino-pyrimidin-4-yl)-1-(2-pyridin-2-yl-ethyl)-urea; 
 3-(2,6-Dichloro-3-methoxy-phenyl)-1-ethyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3-methoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3-methoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3-methoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3-methoxy-phenyl)-1-(6-methoxy-pyridin-3-ylmethyl)-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-ethyl-1-{6-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-(6-isopropylamino-pyrimidin-4-yl)-urea; 
 (2,6-dichloro-phenyl)-carbamic acid 4-{6-[3-(2,6-dichloro-phenyl)-ureido]-pyrimidin-4-ylamino}-cyclohexylester; 
 1-(6-Isopropylamino-pyrimidin-4-yl)-3-(2,4,6-trichloro-phenyl)-urea; 
 1-(2,6-Dichloro-phenyl)-3-(6-isopropylamino-pyrimidin-4-yl)-urea; 
 1-{6-[4-(1-Methyl-piperidin-4-ylmethoxy)-phenylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-{6-[4-(1-methyl-piperidin-4-ylmethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(1-methyl-piperidin-4-ylmethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,5-Dichloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-{6-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-{6-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-3-(2,4,5-trichloro-phenyl)-urea; 
 1-(3,4-Dichloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,3-Dichloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(5-Chloro-2-methoxy-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-{6-[3-(1-methyl-piperidin-4-ylmethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[3-(1-methyl-piperidin-4-ylmethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-{6-[3-(1-Methyl-piperidin-4-ylmethoxy)-phenylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-{6-[4-(4-Methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-{6-[4-(4-Methyl-piperazin-1-carbonyl)-phenylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-{6-[3-(4-Methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-{6-[(trans)-4-(tert-Butyl-dimethyl-silanyloxy)-cyclohexylamino]-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-{6-((trans)-4-Hydroxy-cyclohexylamino)-pyrimidin-4-yl}-3-(2,4,6-trichloro-phenyl)-urea; 
 1-{6-[(trans)-4-(tert-Butyl-dimethyl-silanyloxy)-cyclohexylamino]-pyrimidin-4-yl}-3-(2-chloro-6-methyl-phenyl)-urea; 
 1-(2-Chloro-6-methyl-phenyl)-3-[6-((trans)-4-hydroxy-cyclohexylamino)-pyrimidin-4-yl]-urea; 
 1-{6-[(trans)-4-(tert-Butyl-dimethyl-silanyloxy)-cyclohexylamino]-pyrimidin-4-yl}-3-(2,6-dichloro-phenyl)-urea; 
 1-(2,6-Dichloro-phenyl)-3-[6-((trans)-4-hydroxy-cyclohexylamino)-pyrimidin-4-yl]-urea; 
 1-(2-Chloro-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Bromo-phenyl)-3-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Bromo-phenyl)-3-{6-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(3-morpholin-4-yl-propoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Bromo-phenyl)-3-{6-[4-(3-morpholin-4-yl-propoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Bromo-phenyl)-3-{6-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Chloro-phenyl)-3-{6-[4-(3-diethylamino-propoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-phenyl)-3-{6-[4-(3-diethylamino-propoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2-Bromo-phenyl)-3-{6-[4-(3-diethylamino-propoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-[6-(4-Diethylamino-phenylamino)-pyrimidin-4-yl]-3-(2,6-difluoro-phenyl)-urea; 
 1-(2,6-Difluoro-phenyl)-3-[6-(3-dimethylamino-phenylamino)-pyrimidin-4-yl]-urea; 
 1-(2,6-Dichloro-phenyl)-3-[6-(4-diethylamino-phenylamino)-pyrimidin-4-yl]-urea; 
 1-(2,6-Dichloro-phenyl)-3-[6-(4-morpholin-4-yl-phenylamino)-pyrimidin-4-yl]-urea; 
 1-(2,6-Difluoro-phenyl)-3-[6-(4-morpholin-4-yl-phenylamino)-pyrimidin-4-yl]-urea; 
 3-(2,6-Dichloro-phenyl)-1-[6-(4-diethylamino-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 3-(2,6-Dichloro-phenyl)-1-{6-[4-(1-hydroxy-1-methyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 1-(2,6-Dichloro-phenyl)-3-[6-(6-methoxy-pyridin-3-ylamino)-pyrimidin-4-yl]-urea; 
 3-(2,6-Dichloro-phenyl)-1-methyl-1-[6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-urea; 
 1-[6-(3-Cyano-phenylamino)-pyrimidin-4-yl]-3-(2,6-dichloro-phenyl)-1-methyl-urea; 
 1-(2,6-Dichloro-phenyl)-3-[6-(4-fluoro-phenylamino)-pyrimidin-4-yl]-urea; 
 1-[6-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-3-(4-methoxy-phenyl)-1-methyl-urea; 
 3-(2,6-Dichloro-phenyl)-1-methyl-1-[6-(4-morpholin-4-yl-phenylamino)-pyrimidin-4-yl]-urea; 
 3-(2,6-Dichloro-phenyl)-1-[6-(2,4-difluoro-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 1-(2,6-Dichloro-phenyl)-3-[6-(3-dimethylamino-phenylamino)-pyrimidin-4-yl]-urea; 
 3-(2,6-Dichloro-phenyl)-1-[6-(3-dimethylamino-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 1-[6-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-1-methyl-3-(3-trifluoro-methyl-phenyl)-urea; 
 3-(3-Chloro-phenyl)-1-[6-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 3-(2,6-Dichloro-phenyl)-1-[6-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2,6-dichloro-phenyl)-1-methyl-urea; 
 1-(2-Chloro-phenyl)-3-{6-[4-(3-morpholin-4-yl-propoxy)-phenylamino]-pyrimidin-4-yl}-urea bis-hydrochloride salt; 
 1-(2-Chloro-phenyl)-3-{6-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2,6-dimethyl-phenyl)-1-methyl-urea; 
 3-(2-Chloro-phenyl)-1-[6-(3-chloro-phenylamino)-pyrimidin-4-yl]-urea; 
 1-(2-Bromo-phenyl)-3-[6-(3-chloro-phenylamino)-pyrimidin-4-yl]-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2-fluoro-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(3-methoxy-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2,5-dimethoxy-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2-trifluoromethyl-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(5-methoxy-2-methyl-phenyl)-urea; 
 1-(3-Chloro-phenyl)-3-[6-(3-chloro-phenylamino)-pyrimidin-4-yl]-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(3,4,5-trimethoxy-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2,6-dichloro-phenyl)-urea; 
 1-(4-Chloro-phenyl)-3-[6-(3-chloro-phenylamino)-pyrimidin-4-yl]-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(3,5-dimethoxy-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-(2,6-dimethyl-phenyl)-urea; 
 1-[6-(3-Chloro-phenylamino)-pyrimidin-4-yl]-3-phenyl-urea; 
 1-(2-Chloro-phenyl)-3-{6-[4-(2-morpholin-4-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-ethyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-dimethylaminomethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-(6-{4-[3-(4-methyl-piperazin-1-yl)-propoxy]-phenylamino}-pyrimidin-4-yl)-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(3-dimethylamino-propyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[3-(4-ethyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-dimethylaminomethyl-phenylamino)-pyrimidin-4-yl]-1-ethyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-[6-(6-trifluoromethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-ethyl-1-{6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-[6-(3-dimethylaminomethyl-phenylamino)-pyrimidin-4-yl]-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(6-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenylamino}-pyrimidin-4-yl)-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-[6-(4-dimethylaminomethyl-3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[3-(4-isopropyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-{[(2-dimethylamino-ethyl)-methyl-amino]-methyl]-phenylamino)-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(1-methyl-piperidin-4-yloxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-{6-[4-(1-methyl-piperidin-4-yloxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-ethyl-{6-[4-(1-methyl-piperidin-4-yloxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(4-dimethylaminomethyl-3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-(6-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenylamino}-pyrimidin-4-yl)-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-[6-(4-dimethylaminomethyl-3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(4-dimethylaminomethyl-3-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-{[(2-dimethylamino-ethyl)-methyl-amino]-methyl]-phenylamino)-pyrimidin-4-yl}-1-methyl-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[3-(4-isopropyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea; 
 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[3-(1-methyl-piperidin-4-yloxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-{6-[3-(1-methyl-piperidin-4-yloxy)-phenylamino]-pyrimidin-4-yl}-urea; 
 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-diethylaminomethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-urea; and 
 3-(2,6-Dichloro-3-trifluoromethyl-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea. 
 
     
     
         32 . The method according to  claim 1  wherein in the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma. 
     
     
         33 . A method for the treatment of cancer comprising administering an effective amount of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or N-oxide thereof to an animal in need of treatment thereof. 
     
     
         34 . The method according to  claim 33  wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma. 
     
     
         35 . A method for the treatment of cancer comprising administering an effective amount of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt thereof to an animal in need of treatment thereof. 
     
     
         36 . The method according to  claim 35  wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma. 
     
     
         37 . A method for the treatment of cancer comprising administering an effective amount of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea to an animal in need of treatment thereof. 
     
     
         38 . The method according to  claim 37  wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma. 
     
     
         39 . A method for the treatment of cancer comprising administering an effective amount of 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea or a pharmaceutically acceptable salt or N-oxide thereof to an animal in need of treatment thereof. 
     
     
         40 . The method according to  claim 39  wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma. 
     
     
         41 . A method for the treatment of cancer comprising administering an effective amount of 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea or a pharmaceutically acceptable salt thereof to an animal in need of treatment thereof. 
     
     
         42 . The method according to  claim 41  wherein the in the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma. 
     
     
         43 . A method for the treatment of cancer comprising administering an effective amount of 1-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea to an animal in need of treatment thereof. 
     
     
         44 . The method according to  claim 43  wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, lung cancer, gastric cancer and multiple myeloma.